Clinical use of lentiviral vectors
Open accessThe DOI matches its Crossref record; 99 of the 101 references it cites were found in a registry or an index; 36 of the 87 sources its claims cite were checked for support.
Abstract
Viral vectors provide an efficient means for modification of eukaryotic cells, and their use is now commonplace in academic laboratories and industry for both research and clinical gene therapy applications. Lentiviral vectors, derived from the human immunodeficiency virus, have been extensively investigated and optimized over the past two decades. Third-generation, self-inactivating lentiviral vectors have recently been used in multiple clinical trials to introduce genes into hematopoietic stem cells to correct primary immunodeficiencies and hemoglobinopathies. These vectors have also been used to introduce genes into mature T cells to generate immunity to cancer through the delivery of chimeric antigen receptors (CARs) or cloned T-cell receptors. CAR T-cell therapies engineered using lentiviral vectors have demonstrated noteworthy clinical success in patients with B-cell malignancies leading to regulatory approval of the first genetically engineered cellular therapy using lentiviral vectors. In this review, we discuss several aspects of lentiviral vectors that will be of interest to clinicians, including an overview of lentiviral vector development, the current uses of viral vectors as therapy for primary immunodeficiencies and cancers, large-scale manufacturing of lentiviral vectors, and long-term follow-up of patients treated with gene therapy products.
Overview
CoChat Summary
## TL;DR
This review explains why third-generation, self-inactivating lentiviral vectors have become important tools for clinical gene therapy, especially for modifying hematopoietic stem cells and T cells. It highlights early clinical success in CAR T-cell therapy and summarizes safety, manufacturing, and regulatory issues that still need long-term follow-up.
## Key findings
- Third-generation, self-inactivating lentiviral vectors have been used in multiple clinical trials to introduce genes into hematopoietic stem cells for primary immunodeficiencies and hemoglobinopathies, and into mature T cells for cancer immunotherapy via CARs or cloned T-cell receptors.
- In a trial using a lentiviral vector to transfer a TCR specific for a peptide shared by NY-ESO-1 and LAGE-1 in multiple myeloma, clinical responses were observed in 16 of 20 patients, with minimal safety concerns.
- CD19-targeted CAR T-cell therapies engineered with lentiviral or retroviral vectors showed strong efficacy in B-cell acute lymphoblastic leukemia, with durable complete response rates in >60% of patients with relapsed or refractory disease, and approximately 40 to 70% complete response rates in non-Hodgkin lymphoma.
- For gene transfer into β-thalassemia, one patient with βE/β0-thalassemia achieved transfusion independence; however, this was associated with a dominant myeloid clone containing a lentiviral vector insertion in the HMGA2 locus.
- The review states that no adverse events attributable to the lentiviral vector were reported in the cited trials of T cells and HSCs, and that no cases of leukemogenesis have been reported to date in gene therapy trials involving lentiviral-vector-modified HSCs or non-dividing T cells.
## Methods
- Narrative review of the development, clinical use, manufacturing, regulatory oversight, and future directions of lentiviral vectors.
- Synthesizes published clinical and preclinical studies across HSC gene therapy, T-cell engineering, cancer vaccines, gene editing, and in vivo delivery; no new primary dataset is presented.
- Summarizes evidence from clinical trials, phase 1/2 studies, and model systems to discuss efficacy and safety.
## Limitations
- The paper explicitly notes that the safety of lentiviral vectors in ex vivo gene transfer into HSCs remains a somewhat open question and that longer follow-up will be necessary to fully establish safety in this setting.
- It states that continued follow-up of patients receiving lentiviral-vector-based gene therapies is still needed to understand long-term safety and efficacy.
- Evident from the text: this is a review article, so its conclusions depend on the quality and completeness of the cited studies rather than on a single controlled primary experiment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Steps of reverse transcription. This figure illustrates the steps involved in the conversion of the single-stranded RNA (ssRNA) genome of HIV into double-stranded DNA (dsDNA). RNA is shown in red and DNA as yellow [1]. The transfer RNA (tRNA) primer (blue ellipse) is base paired to the primer-binding site (PBS) [2]. Reverse transcription is initiated using the reverse transcriptase (RT; purple ellipse) enzyme, and minus-strand DNA synthesis starts from the tRNA primer, copying the U5 and R sequences at the 5′ end of the genome. At this stage, an RNA/DNA duplex is created, and ribonuclease (RNase) H activity of the RT enzyme degrades the viral RNA that has been copied (dotted red line) [3, 4]. The minus-strand DNA has been transferred, using the R sequence found at both ends of the viral RNA, to the 3′ end of the viral RNA, and minus-strand DNA synthesis continues. The HIV-1 genome has two RNase H-resistant polypurine tracts (PPTs) [5]. The two PPTs serve as primers for plus-strand DNA synthesis. One plus-strand is initiated at U3, and one is initiated at the central PPT (cPPT) [6]. Both the plus- and minus-strand DNAs are then elongated, finally resulting in a complete copy of viral RNA with additional sequences at the 5′ and 3′ ends such that viral DNA has an identical copy of U3RU5 at both ends. The plus-strand that was initiated at U3 displaces a segment of the plus-strand that was initiated from the cPPT, creating a small flap called the central flap (cFLAP). LTR long terminal repeat](https://figures.cochat.ai/paper-figures/fa1c4f8df2ca45afaf6a08c8aa7e2468/clinical-use-of-lentiviral-vectors-figure-1.jpg)



Verification
Claims the paper makes
30 Valid · 5 Not valid · 37 Not checked · 43 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Expansions of cells with a common integration site were observed in a gene therapy trial using lentiviral vectors for adrenoleukodystrophy [51].”
§ Clinical use of lentiviral vectors > History of lentiviral vector development > Lentiviral vectors
What the sources say
- Disputedcites [51] Cartier N Hacein-Bey-Abina S Bartholomae CC Veres G Schmidt M Kutschera I Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy Science 2009 326 818 23 10.1126/science.1171242 19892975 sourceExperimental — accuracy not yet measured
In the section on ex vivo lentiviral-mediated ABCD1 transfer (page not supplied), the authors report that no frequent clone reappeared with an increasing count and that no clonal dominance emerged. They also define common integration sites as insertions in the same gene or region in different clones, not cells sharing one insertion site; their presence did not significantly increase after reinfusion. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Additionally, elegant studies by Yamashita et al. [21] demonstrated that the capsid protein of HIV but not MLV enables HIV’s translocation across the nuclear pore.”
§ Clinical use of lentiviral vectors > History of lentiviral vector development > Lentivirus biology The basic genes required for retroviral and lentiviral survival and function are the gag, pol, and env genes; gag encodes structural proteins, pol encodes enzymes required for reverse transcription and integration into the host cell genome, and env encodes the viral envelope glycoprotein [3]. All retroviruses have a similar life cycle. The life cycle begins when the mature virus gains entry to the cell either through direct membrane fusion or receptor-mediated endocytosis facilitated through the binding of glycoproteins within the envelope to their cognate receptors on the target cell’s surface. This initial fusion step is followed by a process of uncoating; at this stage, several viral proteins (including some Gag subunits) dissociate from the viral core. The viral RNA is converted to proviral double-stranded DNA through a complicated multistep process of reverse transcription. The proviral DNA then complexes with viral proteins to facilitate nuclear import and integration into the host genome. The process of integration is assisted by crucial viral proteins, such as integrase, and endogenous host cell transcription factors such as LEDGF [4]. The integrated proviral genome of wild-type lentivirus relies on host machinery to initiate and complete transcription and translation of viral proteins necessary to assemble infectious particles. The viral progeny then exit the cell through a process called budding, in which virions are released into the extracellular space from the plasma membrane unlike other viruses that often bud. Like many enveloped viruses, lentiviruses utilize the endosomal sorting complexes required for transport pathway to execute the complex budding process and release virions into the extracellular space [5]. During the budding process, endogenous membrane proteins present within the host cell can be incorporated into the envelope of the virion such as MHC molecules, which may affect the subsequent disposition of the liberated viral particles. The processes of viral egress and subsequent viral spreading are essential to the life cycle of wild-type lentivirus, but are not germane to the understanding of the fundamental features of replication-incompetent recombinant lentiviral vectors. Two unique steps of the retroviral life cycle, reverse transcription and integration, are integral to how lentiviral vectors function. Following uncoating, the remaining viral nucleic acid and protein complex is often referred to as the reverse transcription complex (RTC). This RTC is actively transported to the chromosomal DNA, where integration may occur [6–9]. During this migration, the viral RNA is converted within the RTC to double-stranded viral DNA by the reverse transcription process. This process begins when a transfer RNA binds to the primer-binding site at the 5′ end of the viral RNA genome (Fig. 1). As the negative-strand of the viral DNA is synthesized by the polymerase activity of the reverse transcriptase enzyme, the viral RNA is degraded by the RNAse H activity of this same enzyme. This process creates a short fragment of negative-sense, single-strand DNA, often referred to as strong-stop copy DNA (sscDNA). This sscDNA fragment is subsequently transferred to the 3′ end of the viral RNA to serve as a primer for the synthesis of the negative-strand viral DNA. In this process, the U3RU5 sequence of the long terminal repeat (LTR) that is essential for the viral life cycle is restored. Priming for the synthesis of the positive-strand viral DNA is accomplished through RNase H-resistant polypurine tracts, one close to the 3′ LTR and the other a central polypurine tract. In summary, the entire process uses multiple priming steps resulting in a complete DNA copy of the viral RNA. This viral DNA has an identical copy of the U3RU5 sequence within the LTR at both ends. As reverse transcription nears completion, the complex can be referred to as a pre-integration complex (PIC). Because there are potentially multiple priming events to synthesize the plus-strand, flaps of overlapping positive-strand DNA can form. It is thought that these flaps are likely repaired by host DNA repair enzymes after the process of integration [10, 11]. Although the central polypurine tracts (or the flaps of DNA they generate) are not essential for the process of reverse transcription, studies with viral vectors suggest that their presence enhances the potency of viral vectors. This may be due to the enhanced rate of second-strand synthesis, which may also protect the RTC from innate restriction factors, such as the apolipoprotein B mRNA editing catalytic polypeptide-like enzyme (APOBEC). However, it has also been suggested that this three-stranded DNA flap may also enhance nuclear import [12, 13]. Whether reverse transcription is completed in the cytoplasm or nucleus is unclear [10, 14]. The precise composition of the RTC may allow for more-effective reverse transcription. The capsid appears to protect the viral nucleic acid from innate sensors; simultaneously, it provides a structure that allows for more-effective reverse transcription with lower error rates. Reverse transcription is more accurate in cell lines than in a cell-free system, but the transcription rate is much slower (70 nt/min vs. 1000 nt/min). This rate is even slower still in primary cells, such as macrophages and resting T cells, which have lower nucleotide pools. The process of transporting the RTC from the cellular envelope to the chromatin of the cell is active, requiring energy [15], and it remains under-investigated; however, recent studies of the integration process have uncovered several host-virus interactions that may facilitate the process. One such model suggests that capsid protein has a fundamental role in the early part of the viral life cycle by utilizing cyclophilin A, cleavage and polyadenylation specificity factor 6 (CPSF6), Nup358, and TNPO3 to orchestrate a coordinated process of capsid uncoating, DNA synthesis, and integration that promotes evasion of the innate response and insertion into preferred areas of chromatin [16]. The steps of integration are (1) tethering (2), 3′ processing/cleavage of a precise number of terminal nucleotides (3), strand transfer, and (4) DNA repair. Important differences between gammaretroviruses (murine leukemia virus [MLV]) and lentiviruses (human immunodeficiency virus [HIV]) have consequences that should be considered when designing gene therapy vectors using retroviruses.
What the sources say
- Partly supportedcites [21] Yamashita M Emerman M Capsid is a dominant determinant of retrovirus infectivity in nondividing cells J Virol 2004 78 5670 8 10.1128/JVI.78.11.5670-5678.2004 15140964 PMC415837 sourceExperimental — accuracy not yet measured
The Abstract reports that replacing HIV capsid sequences with MLV sequences impairs nuclear transport in nondividing cells, supporting a role for capsid in the difference between the viruses. But the Discussion presents HIV capsid dissociation as a proposed way to permit transport, explicitly says HIV capsid does not itself act as a nuclear-localization signal, and does not demonstrate its translocation across a nuclear pore. (LLM, conf=0.87)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This RTC is actively transported to the chromosomal DNA, where integration may occur [6–9].”
§ Clinical use of lentiviral vectors > History of lentiviral vector development > Lentivirus biology The basic genes required for retroviral and lentiviral survival and function are the gag, pol, and env genes; gag encodes structural proteins, pol encodes enzymes required for reverse transcription and integration into the host cell genome, and env encodes the viral envelope glycoprotein [3]. All retroviruses have a similar life cycle. The life cycle begins when the mature virus gains entry to the cell either through direct membrane fusion or receptor-mediated endocytosis facilitated through the binding of glycoproteins within the envelope to their cognate receptors on the target cell’s surface. This initial fusion step is followed by a process of uncoating; at this stage, several viral proteins (including some Gag subunits) dissociate from the viral core. The viral RNA is converted to proviral double-stranded DNA through a complicated multistep process of reverse transcription. The proviral DNA then complexes with viral proteins to facilitate nuclear import and integration into the host genome. The process of integration is assisted by crucial viral proteins, such as integrase, and endogenous host cell transcription factors such as LEDGF [4]. The integrated proviral genome of wild-type lentivirus relies on host machinery to initiate and complete transcription and translation of viral proteins necessary to assemble infectious particles. The viral progeny then exit the cell through a process called budding, in which virions are released into the extracellular space from the plasma membrane unlike other viruses that often bud. Like many enveloped viruses, lentiviruses utilize the endosomal sorting complexes required for transport pathway to execute the complex budding process and release virions into the extracellular space [5]. During the budding process, endogenous membrane proteins present within the host cell can be incorporated into the envelope of the virion such as MHC molecules, which may affect the subsequent disposition of the liberated viral particles. The processes of viral egress and subsequent viral spreading are essential to the life cycle of wild-type lentivirus, but are not germane to the understanding of the fundamental features of replication-incompetent recombinant lentiviral vectors. Two unique steps of the retroviral life cycle, reverse transcription and integration, are integral to how lentiviral vectors function. Following uncoating, the remaining viral nucleic acid and protein complex is often referred to as the reverse transcription complex (RTC). This RTC is actively transported to the chromosomal DNA, where integration may occur [6–9]. During this migration, the viral RNA is converted within the RTC to double-stranded viral DNA by the reverse transcription process. This process begins when a transfer RNA binds to the primer-binding site at the 5′ end of the viral RNA genome (Fig. 1). As the negative-strand of the viral DNA is synthesized by the polymerase activity of the reverse transcriptase enzyme, the viral RNA is degraded by the RNAse H activity of this same enzyme. This process creates a short fragment of negative-sense, single-strand DNA, often referred to as strong-stop copy DNA (sscDNA). This sscDNA fragment is subsequently transferred to the 3′ end of the viral RNA to serve as a primer for the synthesis of the negative-strand viral DNA. In this process, the U3RU5 sequence of the long terminal repeat (LTR) that is essential for the viral life cycle is restored. Priming for the synthesis of the positive-strand viral DNA is accomplished through RNase H-resistant polypurine tracts, one close to the 3′ LTR and the other a central polypurine tract. In summary, the entire process uses multiple priming steps resulting in a complete DNA copy of the viral RNA. This viral DNA has an identical copy of the U3RU5 sequence within the LTR at both ends. As reverse transcription nears completion, the complex can be referred to as a pre-integration complex (PIC). Because there are potentially multiple priming events to synthesize the plus-strand, flaps of overlapping positive-strand DNA can form. It is thought that these flaps are likely repaired by host DNA repair enzymes after the process of integration [10, 11]. Although the central polypurine tracts (or the flaps of DNA they generate) are not essential for the process of reverse transcription, studies with viral vectors suggest that their presence enhances the potency of viral vectors. This may be due to the enhanced rate of second-strand synthesis, which may also protect the RTC from innate restriction factors, such as the apolipoprotein B mRNA editing catalytic polypeptide-like enzyme (APOBEC). However, it has also been suggested that this three-stranded DNA flap may also enhance nuclear import [12, 13]. Whether reverse transcription is completed in the cytoplasm or nucleus is unclear [10, 14]. The precise composition of the RTC may allow for more-effective reverse transcription. The capsid appears to protect the viral nucleic acid from innate sensors; simultaneously, it provides a structure that allows for more-effective reverse transcription with lower error rates. Reverse transcription is more accurate in cell lines than in a cell-free system, but the transcription rate is much slower (70 nt/min vs. 1000 nt/min). This rate is even slower still in primary cells, such as macrophages and resting T cells, which have lower nucleotide pools. The process of transporting the RTC from the cellular envelope to the chromatin of the cell is active, requiring energy [15], and it remains under-investigated; however, recent studies of the integration process have uncovered several host-virus interactions that may facilitate the process. One such model suggests that capsid protein has a fundamental role in the early part of the viral life cycle by utilizing cyclophilin A, cleavage and polyadenylation specificity factor 6 (CPSF6), Nup358, and TNPO3 to orchestrate a coordinated process of capsid uncoating, DNA synthesis, and integration that promotes evasion of the innate response and insertion into preferred areas of chromatin [16]. The steps of integration are (1) tethering (2), 3′ processing/cleavage of a precise number of terminal nucleotides (3), strand transfer, and (4) DNA repair. Important differences between gammaretroviruses (murine leukemia virus [MLV]) and lentiviruses (human immunodeficiency virus [HIV]) have consequences that should be considered when designing gene therapy vectors using retroviruses.
What the sources say
- Partly supportedcites [6] Bukrinsky MI Sharova N McDonald TL Pushkarskaya T Tarpley WG Stevenson M Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection Proc Natl Acad Sci USA 1993 90 6125 9 10.1073/pnas.90.13.6125 7687060 PMC46880 sourceExperimental — accuracy not yet measured
Our copy of Bukrinsky et al. (1993, PNAS 90:6125) contains only the abstract and the reference list (body text not indexed; searches for 'chromosomal DNA', 'active nuclear import', 'reverse transcription complex transported' returned nothing beyond the abstract). The abstract does support the nuclear-import half of the claim: HIV-1 nucleoprotein (preintegration) complexes were isolated from nuclear extracts of acutely infected CD4+ cells, 'possessed integration activity in vitro', and nuclear import of these complexes was analysed with an RT inhibitor showing reverse transcription 'could be completed entirely in the host cell nucleus'. What our copy does not state is the specific destination in the claim — active transport 'to the chromosomal DNA' — nor an explicit description of the transport as an active/energy-dependent process; the concept of active nuclear import appears in this paper only as a cited reference (Bukrinsky et al., 1992, 'Active nuclear import of human immunodeficiency virus type 1 preintegration complexes', PNAS 89:6580), not as a finding reported here. (LLM, conf=0.72)
- Supportedcites [7] Campbell EM Hope TJ HIV-1 capsid: the multifaceted key player in HIV-1 infection Nat Rev Microbiol 2015 13 471 83 10.1038/nrmicro3503 26179359 PMC4876022 source
The Cytoplasmic trafficking section reports dynein-dependent movement of HIV-1 particles toward the nucleus, and the Nuclear import section describes trafficking of the RTC into the nucleus to access target-cell DNA. The CA determinants section describes the subsequent integration of the HIV genome into the host genome. The source thus supports the sentence as a summary of transport followed by possible integration, though it does not describe transport directly to a particular chromosomal site. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [8] Heinzinger NK Bukrinsky MI Haggerty SA Ragland AM Kewalramani V Lee MA The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells Proc Natl Acad Sci USA 1994 91 7311 5 10.1073/pnas.91.15.7311 8041786 PMC44389 source
- Partly supportedcites [9] Hulme AE Perez O Hope TJ Complementary assays reveal a relationship between HIV-1 uncoating and reverse transcription Proc Natl Acad Sci USA 2011 108 9975 80 10.1073/pnas.1014522108 21628558 PMC3116424 sourceExperimental — accuracy not yet measured
The Introduction/Abstract of Hulme et al. (2011) states that 'the released reverse transcription complex (RTC) matures into a double-stranded DNA containing preintegration complex (PIC), which is transported into the nucleus, where it integrates into the chromosomal DNA of the target cell' — so transport to the chromosomal DNA and integration are described, but for the PIC, not for the RTC as the citing sentence asserts. The source nowhere describes this transport as 'active'; the closest is the Introduction's account of a model proposed by others ('uncoating takes place as the reverse transcribing viral genome is transported toward the nucleus... based on fluorescence microscopy observations that both cytoplasmic RTCs associated with or without p24CA can be found on microtubules', credited to reference 11), and the Discussion's support for transport of the reverse transcribing genome to the nucleus. TheRTC-versus-PIC distinction and the 'actively transported' qualifier are therefore not attributable to this source. (LLM, conf=0.75)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The introduction of deletions into the 3'LTR of the viral genome to create self-inactivating (SIN) lentiviral vectors disrupted the promoter/enhancer activity of the LTR, further improving safety [42].”
§ Clinical use of lentiviral vectors > History of lentiviral vector development > Lentiviral vectors
What the sources say
- Supportedcites [42] Dull T Zufferey R Kelly M Mandel RJ Nguyen M Trono D A third-generation lentivirus vector with a conditional packaging system J Virol 1998 72 8463 71 9765382 PMC110254 source
Materials and Methods describes a SIN vector with a deletion in the 3′ LTR from −418 to −18. Results locates the LTR enhancer and part of its core promoter within that deleted region, and the Discussion identifies the self-inactivating design as offering significant biosafety features. The paper frames the safety benefit as predicted, not proven in vivo. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Third-generation lentiviral vectors further improved safety by splitting the viral genome into separate plasmids, making recombinant virus generation even more unlikely (Fig. 2) [42].”
§ Clinical use of lentiviral vectors > History of lentiviral vector development > Lentiviral vectors
What the sources say
- Supportedcites [42] Dull T Zufferey R Kelly M Mandel RJ Nguyen M Trono D A third-generation lentivirus vector with a conditional packaging system J Virol 1998 72 8463 71 9765382 PMC110254 source
The Discussion describes the third-generation vector as packaged by three nonoverlapping constructs and says this split-genome strategy requires multiple recombination events to generate a replication-competent virus. The Abstract calls the conditional packaging system a built-in safeguard against productive recombinants, while noting that its actual biosafety remains to be proven in vivo. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
63 more claims · 14 with their cited sources checked
Create a free account to see all 115 claims and to verify the 13 references still open.
- It may state two separate claims as one. 34
- Probably not a substantial claim. 19
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This has resulted in the regulatory approval of the first genetically engineered cellular therapy using these vector systems.”
From Viral Vector Systems for Gene Therapy: A Comprehensive Literature Review of Progress and Biosafety Challenges (2020) · cites this paper as [106]
The cited source says what the claim attributes to it.
In the citing paper
“HIV-1 derived LV is well known for its efficient and stable transduction in dividing and non-dividing cells.”
From Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through (2022) · cites this paper as [2]
In the citing paper
“CAR T-cell therapies developed using LVVs have been successful in the clinical setting in patients with B-cell malignancies.”
From Viral Vector Systems for Gene Therapy: A Comprehensive Literature Review of Progress and Biosafety Challenges (2020) · cites this paper as [106]
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116 · cited 1×
“double-strand breaks, which can then be followed by homologous recombination to result in gene deletion or point mutations [98].”
BackgroundChimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · cited 1×
“not a result of using viral vectors [74].”
BackgroundIn Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903
A Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341 · cited 1×
“The introduction of deletions into the 3'LTR of the viral genome to create self-inactivating (SIN) lentiviral vectors disrupted the promoter/enhancer activity of the LTR, further improving safety [42].”
MethodProgress and problems with the use of viral vectors for gene therapy
Thomas, C. E., Ehrhardt, A., & Kay, M. A. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1066 · Cited by 2,501 · cited 4×
“U5 lopR R3UTPPvnegagPBSU5R pol cPPT cPPT tRNA tRNA cPPT cPPT cPPT cFLAP gag env PPT U3 RPBS pol gag env PPT U3 RPBS pol gag env PPT U3 RPBS pol gag env PPT U3 LTR RNA-DNA duplex U3 RPBSU5 U5 U5 U5 lopR RT RT LTR RT RT RT Fig.”
BackgroundInfluentialCD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Zack, J. A., Arrigo, S. J., Weitsman, S. R., Go, A. S., Haislip, A., & Chen, I. S. Y. (1990) · Cell · doi:10.1016/0092-8674(90)90802-l · Cited by 1,517
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508 · cited 2×
“Lentiviral vector-based gene transfer into CD34+HSCs has subsequently been applied in the treatment of several genetic diseases, including β-thalassemia [67], X-linked adrenoleukodystrophy [51], metachromatic leukodystrophy [68, 69], and Wiskott-Aldrich Syndrome [70].”
BackgroundBurns, J. C., Friedmann, T., Driever, W., Burrascano, M., & Yee, J. K. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8033 · Cited by 1,399 · cited 1×
“VSV-G recognizes a ubiquitously expressed receptor that was most recently identified as the low-density lipoprotein (LDL) receptor [39, 40], allowing the lentiviral vector to transduce a wide range of cells [41].”
BackgroundHowe, S. J., Mansour, M. R., Schwarzwaelder, K., Bartholomae, C., Hubank, M., Kempski, H., Brugman, M. H., Pike-Overzet, K., Chatters, S. J., de Ridder, D., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35798 · Cited by 1,286 · cited 1×
“However, oncogenic potential is likely highly dependent on context, particularly preexisting genetic aberrations in treated patients [49].”
BackgroundTransfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276 · cited 2×
“patient with β/β-thalassemia achieved independence from transfusion [67].”
BackgroundMilone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197 · cited 1×
“However, promoters vary substantially in their activity in primary cells, such as CD34+ stem cells and T cells [43], with the cytomegalovirus promoter showing greater variation with T-cell activation than with constitutively active cellular promoters, such as elongation factor 1-α [44].”
BackgroundSelf-citationLentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy
Biffi, A., Montini, E., Lorioli, L., Cesani, M., Fumagalli, F., Plati, T., Baldoli, C., Martino, S., Calabria, A., Canale, S., et al. (2013) · Science · doi:10.1126/science.1233158 · Cited by 1,180
Koike-Yusa, H., Li, Y., Tan, E.-P., Velasco-Herrera, M. D. C., & Yusa, K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2800 · Cited by 1,064 · cited 1×
“One study used a lentiviral CRISPR guide RNA library to introduce targeted mutations into embryonic stem cells, and subsequent identification of phenotypic mutants demonstrated the efficacy of this approach as an alternative to genetic screening using RNA interference [99].”
Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome
Aiuti, A., Biasco, L., Scaramuzza, S., Ferrua, F., Cicalese, M. P., Baricordi, C., Dionisio, F., Calabria, A., Giannelli, S., Castiello, M. C., et al. (2013) · Science · doi:10.1126/science.1233151 · Cited by 1,025 · cited 1×
“Lentiviral vector-based gene transfer into CD34+HSCs has subsequently been applied in the treatment of several genetic diseases, including β-thalassemia [67], X-linked adrenoleukodystrophy [51], metachromatic leukodystrophy [68, 69], and Wiskott-Aldrich Syndrome [70].”
BackgroundTurnover of naive- and memory-phenotype T cells.
Tough, D. F., & Sprent, J. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.4.1127 · Cited by 869
Heinzinger, N. K., Bukinsky, M. I., Haggerty, S. A., Ragland, A. M., Kewalramani, V, Lee, M. A., Gendelman, H. E., Ratner, L., Stevenson, M., & Emerman, M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.15.7311 · Cited by 854
Specific HIV integration sites are linked to clonal expansion and persistence of infected cells
Maldarelli, F., Wu, X., Su, L., Simonetti, F. R., Shao, W., Hill, S., Spindler, J., Ferris, A. L., Mellors, J. W., Kearney, M. F., et al. (2014) · Science · doi:10.1126/science.1254194 · Cited by 849 · cited 1×
“However, as already discussed, clonal expansions can occur when lentiviral vectors integrate within known oncogenes; therefore, the risk of mutagenesis may be lower when using lentiviral vectors but is not eliminated [59].”
BackgroundGlobal Manufacturing of CAR T Cell Therapy
Levine, B. L., Miskin, J., Wonnacott, K., & Keir, C. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2016.12.006 · Cited by 765 · cited 1×
“Following purification, the eluted fractions undergo a series of filtration steps for sterilization purposes and to remove any remaining cellular debris [62, 63].”
BackgroundProliferation of cells with HIV integrated into cancer genes contributes to persistent infection
Wagner, T. A., McLaughlin, S., Garg, K., Cheung, C. Y. K., Larsen, B. B., Styrchak, S., Huang, H. C., Edlefsen, P. T., Mullins, J. I., & Frenkel, L. M. (2014) · Science · doi:10.1126/science.1256304 · Cited by 677 · cited 7×
“Differentiating these from natural HIV-1 infection will, therefore, be important, and require more extensive testing.”
BackgroundInfluentialLDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus
Finkelshtein, D., Werman, A., Novick, D., Barak, S., & Rubinstein, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214441110 · Cited by 656 · cited 1×
“VSV-G recognizes a ubiquitously expressed receptor that was most recently identified as the low-density lipoprotein (LDL) receptor [39, 40], allowing the lentiviral vector to transduce a wide range of cells [41].”
BackgroundLe, D. T., Wang-Gillam, A., Picozzi, V., Greten, T. F., Crocenzi, T., Springett, G., Morse, M., Zeh, H., Cohen, D., Fine, R. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.4244 · Cited by 611
Quiescent T Lymphocytes as an Inducible Virus Reservoir in HIV-1 Infection
Bukrinsky, M. I., Stanwick, T. L., Dempsey, M. P., & Stevenson, M. (1991) · Science · doi:10.1126/science.1925601 · Cited by 590 · cited 1×
“Around the same time, studies of patient cells demonstrated that quiescent CD4+ T cells contained HIV DNA [26].”
BackgroundAnalysis of histone 2B-GFP retention reveals slowly cycling hematopoietic stem cells
Foudi, A., Hochedlinger, K., Van Buren, D., Schindler, J. W., Jaenisch, R., Carey, V., & Hock, H. (2009) · Nature Biotechnology · doi:10.1038/nbt.1517 · Cited by 586 · cited 1×
“Similarly, slow cycling is also observed with HSCs, and long-term repopulating potential is inversely correlated with cycling [47].”
BackgroundMontini, E., Cesana, D., Schmidt, M., Sanvito, F., Bartholomae, C. C., Ranzani, M., Benedicenti, F., Sergi, L. S., Ambrosi, A., Ponzoni, M., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37630 · Cited by 571 · cited 2×
“[56] demonstrated that by swapping regions of retroviral and lentiviral LTRs, lentiviral vectors can induce insertional mutagenesis when bearing the strong promoter/enhancer elements from retroviruses.”
BackgroundMcDougal, J. S., Mawle, A., Cort, S. P., Nicholson, J. K. A., Cross, G. D., Scheppler-Campbell, J. A., Hicks, D., & Sligh, J. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.5.3151 · Cited by 534 · cited 1×
“For many years, the consensus in the field was that HIV did not infect quiescent CD4+ T cells in the G0 stage of the life cycle but could infect activated CD4+ T cells [24, 25].”
BackgroundSessa, M., Lorioli, L., Fumagalli, F., Acquati, S., Redaelli, D., Baldoli, C., Canale, S., Lopez, I. D., Morena, F., Calabria, A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30374-9 · Cited by 502 · cited 1×
“Lentiviral vector-based gene transfer into CD34+HSCs has subsequently been applied in the treatment of several genetic diseases, including β-thalassemia [67], X-linked adrenoleukodystrophy [51], metachromatic leukodystrophy [68, 69], and Wiskott-Aldrich Syndrome [70].”
BackgroundWang, G. P., Ciuffi, A., Leipzig, J., Berry, C. C., & Bushman, F. D. (2007) · Genome Research · doi:10.1101/gr.6286907 · Cited by 457 · cited 1×
“It also appears that DNA sequences that are highly bent due to wrapping around nucleosomes are favored [20].”
BackgroundBukrinsky, M. I., Sharova, N., McDonald, T. L., Pushkarskaya, T., Tarpley, W. G., & Stevenson, M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.13.6125 · Cited by 451 · cited 1×
“One plus-strand is initiated at U3, and one is initiated at the central PPT (cPPT) [6].”
BackgroundEditing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer
Provasi, E., Genovese, P., Lombardo, A., Magnani, Z., Liu, P.-Q., Reik, A., Chu, V., Paschon, D. E., Zhang, L., Kuball, J., et al. (2012) · Nature Medicine · doi:10.1038/nm.2700 · Cited by 448 · cited 9×
“NILVs have been used effectively as a vaccination strategy in pre-clinical models, resulting in cellular and humoral immunity as well as anti-tumor immunity [88].”
MethodInfluentialHIV-1 capsid: the multifaceted key player in HIV-1 infection
Campbell, E. M., & Hope, T. J. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3503 · Cited by 430
Cytokine Signals Are Sufficient for HIV-1 Infection of Resting Human T Lymphocytes
Unutmaz, D., KewalRamani, V. N., Marmon, S., & Littman, D. R. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.11.1735 · Cited by 427 · cited 1×
“Treatment with several cytokines, such as interleukin 7, overcomes this limitation [36] and enhances cell survival, as G0 T cells are also prone to die soon after HIV infection [37].”
BackgroundModlich, U., Navarro, S., Zychlinski, D., Maetzig, T., Knoess, S., Brugman, M. H., Schambach, A., Charrier, S., Galy, A., Thrasher, A. J., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.179 · Cited by 387 · cited 1×
“SIN lentiviral vectors were shown to have a lower risk of insertional oncogenesis than gammaretroviral vectors in side-by-side comparisons of model systems [56, 57], and a mouse model of clinically relevant SIN lentiviral vectors showed that the genotoxic potential of lentiviral vectors can be diminished Fig.”
BackgroundClonally expanded CD4 + T cells can produce infectious HIV-1 in vivo
Simonetti, F. R., Sobolewski, M. D., Fyne, E., Shao, W., Spindler, J., Hattori, J., Anderson, E. M., Watters, S. A., Hill, S., Wu, X., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522675113 · Cited by 372 · cited 7×
“Differentiating these from natural HIV-1 infection will, therefore, be important, and require more extensive testing.”
BackgroundInfluentialRetroviral DNA integration: viral and cellular determinants of target-site selection
Lewinski, M. K., Yamashita, M., Emerman, M., Ciuffi, A., Marshall, H., Crawford, G., Collins, F., Shinn, P., Leipzig, J., Hannenhalli, S., et al. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020060 · Cited by 364 · cited 1×
“Each class of retrovirus has its characteristic preference [17, 18].”
Lentiviral Vectors in Gene Therapy: Their Current Status and Future Potential
Escors, D., & Breckpot, K. (2010) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-010-0063-4 · Cited by 344 · cited 2×
“encodes structural proteins, pol encodes enzymes required for reverse transcription and integration into the host cell genome, and env encodes the viral envelope glycoprotein [3].”
BackgroundNuclear architecture dictates HIV-1 integration site selection
Marini, B., Kertesz-Farkas, A., Ali, H., Lucic, B., Lisek, K., Manganaro, L., Pongor, S., Luzzati, R., Recchia, A., Mavilio, F., et al. (2015) · Nature · doi:10.1038/nature14226 · Cited by 335 · cited 1×
“genes are closer to the nuclear pore [23].”
BackgroundCapsid Is a Dominant Determinant of Retrovirus Infectivity in Nondividing Cells
Yamashita, M., & Emerman, M. (2004) · Journal of Virology · doi:10.1128/jvi.78.11.5670-5678.2004 · Cited by 325 · cited 1×
“Although the process of nuclear import is still largely not understood, viral proteins within the PIC, such as capsid, as well as elements of the reverse transcribed host genome are thought to be necessary for transport through the nuclear pore [19, 21].”
Background(2013) · PubMed · Cited by 308
HIV‐1 DNA Flap formation promotes uncoating of the pre‐integration complex at the nuclear pore
Arhel, N. J., Souquere‐Besse, S., Munier, S., Souque, P., Guadagnini, S., Rutherford, S., Prévost, M., Allen, T. D., & Charneau, P. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601740 · Cited by 295 · cited 1×
“However, it has also been suggested that this three-stranded DNA flap may also enhance nuclear import [12, 13].”
BackgroundProduction of lentiviral vectors
Merten, O.-W., Hebben, M., & Bovolenta, C. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.17 · Cited by 294
Maldarelli, F., Wu, X., Su, L., Simonetti, F., Wells, D., Shao, W., Spindler, J., Ferris, A., Mellors, J., Kearney, M., et al. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000479721.09749.2d · Cited by 294
Complementary assays reveal a relationship between HIV-1 uncoating and reverse transcription
Hulme, A. E., Perez, O., & Hope, T. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014522108 · Cited by 276
In vivo estimates of division and death rates of human T lymphocytes.
Mclean, A. R., & Michie, C. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3707 · Cited by 270
Suhoski, M. M., Golovina, T. N., Aqui, N. A., Tai, V. C., Varela-Rohena, A., Milone, M. C., Carroll, R. G., Riley, J. L., & June, C. H. (2007) · Molecular Therapy · doi:10.1038/mt.sj.6300134 · Cited by 266
Self-citationPD‐L1 co‐stimulation contributes to ligand‐induced T cell receptor down‐modulation on CD8 + T cells
Karwacz, K., Bricogne, C., MacDonald, D., Arce, F., Bennett, C. L., Collins, M., & Escors, D. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201100165 · Cited by 265 · cited 1×
“stimulatory signals on dendritic cells to further enhance their efficacy [92, 93].”
BackgroundPhilippe, S., Sarkis, C., Barkats, M., Mammeri, H., Ladroue, C., Petit, C., Mallet, J., & Serguera, C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606197103 · Cited by 249 · cited 1×
“viral genome remains present in the cell as an episome rather than integrating into the host genomic DNA [87].”
BackgroundThemis, M., Waddington, S. N., Schmidt, M., von Kalle, C., Wang, Y., Al-Allaf, F., Gregory, L. G., Nivsarkar, M., Themis, M., Holder, M. V., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.07.358 · Cited by 243 · cited 1×
“Lentiviral vectors can also insert near oncogenes, and tumor formation has been noted in at least one model that used a non-primate lentivirus-derived vector to transduce embryonic cells [50].”
BackgroundAmirache, F., Lévy, C., Costa, C., Mangeot, P.-E., Torbett, B. E., Wang, C. X., Nègre, D., Cosset, F.-L., & Verhoeyen, E. (2014) · Blood · doi:10.1182/blood-2013-11-540641 · Cited by 197 · cited 1×
“VSV-G recognizes a ubiquitously expressed receptor that was most recently identified as the low-density lipoprotein (LDL) receptor [39, 40], allowing the lentiviral vector to transduce a wide range of cells [41].”
BackgroundUncovering and Dissecting the Genotoxicity of Self-inactivating Lentiviral Vectors In Vivo
Cesana, D., Ranzani, M., Volpin, M., Bartholomae, C., Duros, C., Artus, A., Merella, S., Benedicenti, F., Sergi Sergi, L., Sanvito, F., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.3 · Cited by 189 · cited 1×
“by the inclusion of an engineered chromatin insulator cassette [58].”
BackgroundLentiviral Vector Gene Transfer of Endostatin/Angiostatin for Macular Degeneration (GEM) Study
Campochiaro, P. A., Lauer, A. K., Sohn, E. H., Mir, T. A., Naylor, S., Anderton, M. C., Kelleher, M., Harrop, R., Ellis, S., & Mitrophanous, K. A. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.117 · Cited by 186 · cited 1×
“In vivo gene delivery using a lentiviral vector has also been applied clinically to the eye [80].”
MethodSwiggard, W. J., Baytop, C., Yu, J. J., Dai, J., Li, C., Schretzenmair, R., Theodosopoulos, T., & O'Doherty, U. (2005) · Journal of Virology · doi:10.1128/jvi.79.22.14179-14188.2005 · Cited by 182 · cited 1×
“Although most current gene therapy approaches activate T cells to divide before transduction, the ability of HIV-1 to transduce non-dividing T cells in the G0 state [30] dependent upon the importation of the PIC across an intact nuclear envelope provides some hypothetical advantages for use in gene therapy.”
BackgroundSelf-citationEvidence that T cell activation is required for HIV-1 entry in CD4+ lymphocytes.
Gowda, S. D., Stein, B. S., Mohagheghpour, N., Benike, C. J., & Engleman, E. G. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.142.3.773 · Cited by 174 · cited 1×
“For many years, the consensus in the field was that HIV did not infect quiescent CD4+ T cells in the G0 stage of the life cycle but could infect activated CD4+ T cells [24, 25].”
BackgroundSirven, A., Ravet, E., Charneau, P., Zennou, V., Coulombel, L., Guétard, D., Pflumio, F., & Dubart-Kupperschmitt, A. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0282 · Cited by 163 · cited 1×
“However, promoters vary substantially in their activity in primary cells, such as CD34+ stem cells and T cells [43], with the cytomegalovirus promoter showing greater variation with T-cell activation than with constitutively active cellular promoters, such as elongation factor 1-α [44].”
BackgroundLiver-directed lentiviral gene therapy in a dog model of hemophilia B
Cantore, A., Ranzani, M., Bartholomae, C. C., Volpin, M., Valle, P. D., Sanvito, F., Sergi, L. S., Gallina, P., Benedicenti, F., Bellinger, D., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1405 · Cited by 158 · cited 1×
“A phase 1/2 study of a non-primate lentiviral vector based upon the equine infectious anemia virus (EIAV) expressing three genes involved in dopamine metabolism demonstrated the safety of local lentiviral gene delivery into the central nervous system with some evidence of clinical benefit [79].”
BackgroundBaekelandt, V, Eggermont, K., Michiels, M., Nuttin, B., & Debyser, Z. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302094 · Cited by 153 · cited 1×
“The purity of the product is critical; debris from the packaging cells can easily be collected along with the vector product, and these impurities may cause inflammatory responses in vitro and in vivo [64].”
BackgroundPace, M. J., Graf, E. H., Agosto, L. M., Mexas, A. M., Male, F., Brady, T., Bushman, F. D., & O'Doherty, U. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002818 · Cited by 144 · cited 1×
“VSV-G receptor-mediated endocytosis does not result in efficient infection of resting CD4+ T cells [33, 34] due to limited endocytosis [34, 35].”
BackgroundSelf-citationNonproductive Human Immunodeficiency Virus Type 1 Infection in Nucleoside-Treated G 0 Lymphocytes
Korin, Y. D., & Zack, J. A. (1999) · Journal of Virology · doi:10.1128/jvi.73.8.6526-6532.1999 · Cited by 133 · cited 1×
“Over time, it was recognized that the low level of nucleotides and high expression level of restriction factors in resting CD4+ T cells slowed the rate of reverse transcription [28, 29] and reduced the potential to infect resting CD4+ T cells directly”
BackgroundTargeting dendritic cell signaling to regulate the response to immunization
Escors, D., Lopes, L., Lin, R., Hiscott, J., Akira, S., Davis, R. J., & Collins, M. K. (2008) · Blood · doi:10.1182/blood-2007-11-122408 · Cited by 116 · cited 1×
“used to constitutively activate the MAP kinase pathway in dendritic cells, which resulted in enhanced anti-tumor responses in mice [94].”
MethodStem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity
Wu, C., & Dunbar, C. E. (2011) · Frontiers of Medicine · doi:10.1007/s11684-011-0159-1 · Cited by 114 · cited 1×
“This is suggested by clinical data in which the only cases of insertional mutagenesis were reported in genetically modified proliferative HSCs rather than quiescent cell types [48].”
BackgroundPatient monitoring and follow‐up in lentiviral clinical trials
McGarrity, G. J., Hoyah, G., Winemiller, A., Andre, K., Stein, D., Blick, G., Greenberg, R. N., Kinder, C., Zolopa, A., Binder‐Scholl, G., et al. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2691 · Cited by 109 · cited 1×
“No adverse events attributable to the lentiviral vector were reported in this trial, which included up to 8 years of follow-up in some patients [66].”
BackgroundConstruction of stable packaging cell lines for clinical lentiviral vector production
Sanber, K. S., Knight, S. B., Stephen, S. L., Bailey, R., Escors, D., Minshull, J., Santilli, G., Thrasher, A. J., Collins, M. K., & Takeuchi, Y. (2015) · Scientific Reports · doi:10.1038/srep09021 · Cited by 108 · cited 1×
“Recently, a method for generating clinical-grade stable packaging cell lines that continuously produce lentiviral vectors was reported [65].”
MethodTargeted Genome Modifications Using Integrase-deficient Lentiviral Vectors
Cornu, T. I., & Cathomen, T. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300345 · Cited by 105 · cited 1×
“NILVs can also be co-transduced into cells with zinc finger nucleases, which facilitate recombination of DNA encoded in the vector with a specific site in the host DNA [89].”
BackgroundMiller, M. D., Wang, B., & Bushman, F. D. (1995) · Journal of Virology · doi:10.1128/jvi.69.6.3938-3944.1995 · Cited by 96 · cited 1×
“It is thought that these flaps are likely repaired by host DNA repair enzymes after the process of integration [10, 11].”
BackgroundA model for cofactor use during HIV-1 reverse transcription and nuclear entry
Hilditch, L., & Towers, G. J. (2014) · Current Opinion in Virology · doi:10.1016/j.coviro.2013.11.003 · Cited by 91
Karwacz, K., Mukherjee, S., Apolonia, L., Blundell, M. P., Bouma, G., Escors, D., Collins, M. K., & Thrasher, A. J. (2009) · Journal of Virology · doi:10.1128/jvi.02519-08 · Cited by 87 · cited 1×
“NILVs have been used effectively as a vaccination strategy in pre-clinical models, resulting in cellular and humoral immunity as well as anti-tumor immunity [88].”
MethodA Self-restricted CRISPR System to Reduce Off-target Effects
Chen, Y., Liu, X., Zhang, Y., Wang, H., Ying, H., Liu, M., Li, D., Lui, K. O., & Ding, Q. (2016) · Molecular Therapy · doi:10.1038/mt.2016.172 · Cited by 81 · cited 1×
“[100] described an approach to limit the duration of editing by co-expressing a guide RNA that recognizes the CAS9 itself targeting the expression cassette to be destroyed.”
MethodReverse Transcription of Retroviruses and LTR Retrotransposons
Hughes, S. H. (2015) · Microbiology Spectrum · doi:10.1128/microbiolspec.mdna3-0027-2014 · Cited by 72
Milani, M., Annoni, A., Bartolaccini, S., Biffi, M., Russo, F., Di Tomaso, T., Raimondi, A., Lengler, J., Holmes, M. C., Scheiflinger, F., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201708148 · Cited by 72 · cited 1×
“Gene editing of packaging cells to generate lines that lack HLA class I can enhance the stability of lentiviral vectors in serum [81].”
BackgroundDemeulemeester, J., De Rijck, J., Gijsbers, R., & Debyser, Z. (2015) · BioEssays · doi:10.1002/bies.201500051 · Cited by 71 · cited 2×
“The tethering mechanism of MLV results in insertion sites within enhancers, and involves interactions between the p12 MLV protein with BRD2,3,4 (bromodomain and external domain proteins 2, 3, and 4) [19].”
BackgroundLarge-scale Clinical-grade Retroviral Vector Production in a Fixed-Bed Bioreactor
Wang, X., Olszewska, M., Qu, J., Wasielewska, T., Bartido, S., Hermetet, G., Sadelain, M., & Rivière, I. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000072 · Cited by 70 · cited 1×
“Once generated, vector stocks have been reported to remain stable for up to 9 years when cryopreserved at −80 °C [61].”
BackgroundWrapping up the bad news – HIV assembly and release
Meng, B., & Lever, A. M. (2013) · Retrovirology · doi:10.1186/1742-4690-10-5 · Cited by 68 · cited 2×
“Like many enveloped viruses, lentiviruses utilize the endosomal sorting complexes required for transport pathway to execute the complex budding process and release virions into the extracellular space [5].”
BackgroundBobisse, S., Rondina, M., Merlo, A., Tisato, V., Mandruzzato, S., Amendola, M., Naldini, L., Willemsen, R. A., Debets, R., Zanovello, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0494 · Cited by 62 · cited 1×
“the Melan-A/MART-1 antigen [73], and a phase 2 trial of T cells transduced with a lentivirus to express MART-1 in patients with metastatic melanoma is ongoing.”
BackgroundPlesa, G., Dai, J., Baytop, C., Riley, J. L., June, C. H., & O'Doherty, U. (2007) · Journal of Virology · doi:10.1128/jvi.01745-07 · Cited by 59
Self-citationBear, A. S., Morgan, R. A., Cornetta, K., June, C. H., Binder-Scholl, G., Dudley, M. E., Feldman, S. A., Rosenberg, S. A., Shurtleff, S. A., Rooney, C. M., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.288 · Cited by 59 · cited 10×
“Patients can be monitored for RCRs/RCLs through polymerase chain reaction or serological assays, and the FDA suggests that patients be monitored for recombinant virus every 3 months for the first year after receiving gene therapy.”
BackgroundInfluentialCellular and viral determinants of retroviral nuclear entry
Hamid, F. B., Kim, J., & Shin, C.-G. (2016) · Canadian Journal of Microbiology · doi:10.1139/cjm-2015-0350 · Cited by 48 · cited 1×
“The process of transporting the RTC from the cellular envelope to the chromatin of the cell is active, requiring energy [15], and it remains under-investigated; however, recent studies of the integration process have”
BackgroundSundarasetty, B. S., Chan, L., Darling, D., Giunti, G., Farzaneh, F., Schenck, F., Naundorf, S., Kuehlcke, K., Ruggiero, E., Schmidt, M., et al. (2015) · Gene Therapy · doi:10.1038/gt.2015.43 · Cited by 47 · cited 1×
“stimulatory signals on dendritic cells to further enhance their efficacy [92, 93].”
BackgroundHost Factors in Retroviral Integration and the Selection of Integration Target Sites
Craigie, R., & Bushman, F. D. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.mdna3-0026-2014 · Cited by 45 · cited 5×
“At this stage, an RNA/DNA duplex is created, and ribonuclease (RNase) H activity of the RT enzyme degrades the viral RNA that has been copied (dotted red line) [3, 4].”
BackgroundInfluentialWong, R. W., Mamede, J. I., & Hope, T. J. (2015) · Journal of Virology · doi:10.1128/jvi.01669-15 · Cited by 45 · cited 1×
“proximity to the nuclear pore also plays a role in integration site selection [22].”
BackgroundArhel, N. J., Souquère, S., & Charneau, P. (2006) · Retrovirology · doi:10.1186/1742-4690-3-38 · Cited by 45
Agosto, L. M., Yu, J. J., Liszewski, M. K., Baytop, C., Korokhov, N., Humeau, L. M., & O'Doherty, U. (2009) · Journal of Virology · doi:10.1128/jvi.00220-09 · Cited by 43 · cited 1×
“VSV-G receptor-mediated endocytosis does not result in efficient infection of resting CD4+ T cells [33, 34] due to limited endocytosis [34, 35].”
BackgroundSelf-citationLentiviral Vectors in Cancer Immunotherapy
Oldham, R. A. A., Berinstein, E. M., & Medin, J. A. (2015) · Immunotherapy · doi:10.2217/imt.14.108 · Cited by 42 · cited 1×
“Currently, ongoing phase 1 and phase 2 clinical trials are using autologous T cells that have been transduced to express the tumor antigens NY-ESO-1, MART-1, WT-1, and others [71].”
BackgroundZhou, S., Fatima, S., Ma, Z., Wang, Y.-D., Lu, T., Janke, L. J., Du, Y., & Sorrentino, B. P. (2016) · Molecular Therapy · doi:10.1038/mt.2016.55 · Cited by 42 · cited 1×
“An assay developed to test the oncogenic potential of gammaretroviral and lentiviral vectors may further improve safety when designing vectors for clinical use [60].”
MethodChen, J., Reeves, L., & Cornetta, K. (2001) · Human Gene Therapy · doi:10.1089/104303401450979 · Cited by 38
3D hotspots of recurrent retroviral insertions reveal long-range interactions with cancer genes
Babaei, S., Akhtar, W., de Jong, J., Reinders, M., & de Ridder, J. (2015) · Nature Communications · doi:10.1038/ncomms7381 · Cited by 37
Thomas, D. C., Voronin, Y. A., Nikolenko, G. N., Chen, J., Hu, W.-S., & Pathak, V. K. (2007) · Journal of Virology · doi:10.1128/jvi.02471-06 · Cited by 36 · cited 1×
“scription is completed in the cytoplasm or nucleus is unclear [10, 14].”
BackgroundSauter, C. S., Riviere, I., Bernal, Y., Wang, X., Purdon, T., Yoo, S., Moskowitz, C. H., Giralt, S., Matasar, M. J., Curran, K. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8515 · Cited by 36
Kochenderfer, J. N., Somerville, R., Lu, L., Iwamoto, A., Yang, J. C., Klebanoff, C., Kammula, U., Sherry, R. M., Victoria, S., Yuan, C., et al. (2014) · Blood · doi:10.1182/blood.v124.21.550.550 · Cited by 33
Innate immune defects in HIV permissive cell lines
Rausell, A., Muñoz, M., Martínez, R., Roger, T., Telenti, A., & Ciuffi, A. (2016) · Retrovirology · doi:10.1186/s12977-016-0275-8 · Cited by 29 · cited 2×
“It will be important to understand the effect of these restriction factors as these nuances to lentiviral biology will be important to consider during development of gene therapies based upon these vectors [29].”
BackgroundPizzoferrato, E., Chu, N. R., Hawley, T. S., Lieu, F. H. L., Barber, B. H., Hawley, R. G., Watts, T. H., & Berinstein, N. L. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.18-2217 · Cited by 28
Ciuffi, A. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.02.013 · Cited by 27
Lentiviral vectors in cancer immunotherapy
Lin, S., Wang, B., & Wang, L. (2008) · 国际外科学杂志 · doi:10.3760/cma.j.issn.1673-4203.2008.03.011 · Cited by 23
Pace, M. J., Agosto, L., & O'Doherty, U. (2011) · Journal of Virology · doi:10.1128/jvi.01851-10 · Cited by 19
Self-citationTrinité, B., Chan, C. N., Lee, C. S., & Levy, D. N. (2016) · Journal of Virology · doi:10.1128/jvi.01770-15 · Cited by 19 · cited 1×
“Treatment with several cytokines, such as interleukin 7, overcomes this limitation [36] and enhances cell survival, as G0 T cells are also prone to die soon after HIV infection [37].”
BackgroundFuture directions in chimeric antigen receptor T cell therapy
Maude, S. L. (2017) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000436 · Cited by 18 · cited 2×
“This approach is capable of generating robust clinical responses even in patients with advanced B-cell malignancies that are highly refractory to other existing therapies [1].”
BackgroundGrandchamp, N., Altémir, D., Philippe, S., Ursulet, S., Pilet, H., Serre, M.-C., Lenain, A., Serguera, C., Mallet, J., & Sarkis, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099649 · Cited by 11 · cited 1×
“To allow for long-term expression in dividing cells, a dual NILV vector system was developed to include the integrase of phage phiC31 [91].”
MethodSchuster, S. J., Svoboda, J., Nasta, S., Chong, E. A., Porter, D. L., Landsburg, D. J., Mato, A. R., Bhoj, V. G., Milone, M., Lacey, S. F., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.7564 · Cited by 10
Self-citationRapoport, A., Stadtmauer, E., Melchiori, L., Wong, R., Davila, E., Binder-Scholl, G., Holdich, T., Vogl, D., Weiss, B., Finkelstein, J., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-4701 · Cited by 1 · cited 1×
“In a trial using a lentiviral vector to transfer a TCR specific for a peptide that was shared by NY-ESO-1 and LAGE-1 as a therapy for patients with multiple myeloma, clinical responses were observed in 16 of 20 patients, with minimal safety concerns [72].”
Background
Research works printed but not linked: 1
- Biffi A Montini E Lorioli L Cesani M Fumagalli F Plati T Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy Science 2013 341 1233158 10.1126/science.1233158 23845948 · DOI · Paper page
Cited by
Engineered Virus-like Particles for Efficient in Vivo Delivery of Therapeutic Proteins
Banskota, S., Raguram, A., Suh, S., Du, S. W., Davis, J. R., Choi, E. H., Wang, X., Nielsen, S. C., Newby, G. A., Randolph, P. B., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.021 · Cited by 668
Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities
Tabrizi, S. J., Flower, M. D., Ross, C. A., & Wild, E. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0389-4 · Cited by 538
Therapeutic in vivo delivery of gene editing agents
Raguram, A., Banskota, S., & Liu, D. R. (2022) · Cell · doi:10.1016/j.cell.2022.03.045 · Cited by 522
“Notably, the use of LVs in in vivo gene augmentation therapy clinical studies has raised concerns about genotoxicity, immunogenicity, and the high cost of manufacturing (Milone and O’Doherty, 2018), all of which may limit the use of LVs for in vivo gene editing applications.”
BackgroundNext-generation regulatory T cell therapy
Ferreira, L. M. R., Muller, Y. D., Bluestone, J. A., & Tang, Q. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0041-4 · Cited by 476
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Gong, Y., Klein Wolterink, R. G. J., Wang, J., Bos, G. M. J., & Germeraad, W. T. V. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01083-5 · Cited by 379
Metadata
- Authors
- Milone, M. C., & O’Doherty, U.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Milone, Michael C.
- Venue
- Leukemia
- Published
- 2018-03-22
- Volume
- 32
- Issue
- 7
- Pages
- 1529-1541
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- PMC
- PMC6035154
- OpenAlex
- W2791408070
- Cited by
- 930
- References
- 101
- Citations by year
- 2026: 125 · 2025: 123 · 2024: 156 · 2023: 108 · 2022: 125 · 2021: 126 · 2020: 109 · 2019: 43 · 2018: 14
- FWCI
- 10.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- Locations
- Leukemia (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- lentiviral vectors, gene therapy, CAR T-cell therapy, chimeric antigen receptor, primary immunodeficiency, hemoglobinopathies, hematopoietic stem cells, T cell engineering, B-cell malignancies, long-term follow-up, self-inactivating vectors, viral vector development
- MeSH terms
- Clinical Studies as Topic, Animals, Genetic Engineering, Genetic Vectors, Humans, Transduction, Genetic, Genetic Therapy, Lentivirus, Gene Transfer Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.